191 related articles for article (PubMed ID: 23125297)
1. Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review.
Croke J; Leung E; Segal R; Malone S
BMJ Case Rep; 2012 Nov; 2012():. PubMed ID: 23125297
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
[TBL] [Abstract][Full Text] [Related]
3. Radium-223 for men with hormone-refractory prostate cancer and bone metastases.
Shelley MD; Mason MD
Lancet Oncol; 2007 Jul; 8(7):564-5. PubMed ID: 17613416
[No Abstract] [Full Text] [Related]
4. Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.
Parker C; Zhan L; Cislo P; Reuning-Scherer J; Vogelzang NJ; Nilsson S; Sartor O; O'Sullivan JM; Coleman RE
Eur J Cancer; 2017 Jan; 71():1-6. PubMed ID: 27930924
[TBL] [Abstract][Full Text] [Related]
5. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
Jadvar H; Challa S; Quinn DI; Conti PS
Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
[TBL] [Abstract][Full Text] [Related]
6. Radium-223 chloride: Extending life in prostate cancer patients by treating bone metastases.
Wissing MD; van Leeuwen FW; van der Pluijm G; Gelderblom H
Clin Cancer Res; 2013 Nov; 19(21):5822-7. PubMed ID: 24052017
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and pharmacokinetics of radium-223 in prostate cancer.
Yeku O; Slovin SF
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):843-9. PubMed ID: 25740232
[TBL] [Abstract][Full Text] [Related]
9. Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report.
McNamara MA; George DJ
BMC Cancer; 2015 May; 15():371. PubMed ID: 25948240
[TBL] [Abstract][Full Text] [Related]
10. Four years of clinical experience with Radium-223 for the treatment of castration-resistant prostate cancer.
Álvarez Pérez RM; Delgado García A; García Martínez S; Sanz Viedma S; Palacios Gerona H; Pajares Vinardel M; Jiménez-Hoyuela García JM
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(5):298-304. PubMed ID: 31362912
[TBL] [Abstract][Full Text] [Related]
11. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
Nome R; Hernes E; Bogsrud TV; Bjøro T; Fosså SD
Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
[TBL] [Abstract][Full Text] [Related]
12. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
13. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; Yachnin J; Garkavij M; Strang P; Harmenberg J; Bolstad B; Bruland OS
Lancet Oncol; 2007 Jul; 8(7):587-94. PubMed ID: 17544845
[TBL] [Abstract][Full Text] [Related]
14. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
15. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
[TBL] [Abstract][Full Text] [Related]
16. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
Cheetham PJ; Petrylak DP
Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
[TBL] [Abstract][Full Text] [Related]
18. Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan.
Weng WC; Huang LH; Tseng NC; Ou YC
J Formos Med Assoc; 2022 Oct; 121(10):1929-1937. PubMed ID: 35123846
[TBL] [Abstract][Full Text] [Related]
19. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
20. [Bone-targeted treatment in prostate cancer].
Géczi L; Sinkovics I
Magy Onkol; 2014 Sep; 58(3):199-203. PubMed ID: 25260084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
